Skip to Main Content
National Gaucher Disease Treatment Center
YSM Home

INFORMATION FOR

Clinical Trials

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 (ENGAGE): ClinicalTrial.gov NCT00891202
  • A Phase 3, Randomized, Multicenter, MultiNational, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily vs Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily dose of Genz-112638 (EDGE): ClinicalTrails.gov NCT01074944
  • A Phase 3, Randomized, Multi-Center, Multi-National, Open Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme (ENCORE): ClinicalTrials.gov NCT00943111